Q-omics provides the consensus-scored RABGAP1L-DT profile across patient tissues and cancer cell-line models. RABGAP1L-DT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RABGAP1L-DT is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, RABGAP1L-DT RNA expression shows 14,272 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, HNSC, and TGCT as cancer lineages where RABGAP1L-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RABGAP1L-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RABGAP1L-DT survival associations across molecular data types. RABGAP1L-DT RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RABGAP1L-DT RNA expression–survival associations across cancer types. High RABGAP1L-DT expression shows unfavorable associations in KIRP, ACC, KICH, READ, LIHC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RABGAP1L-DT RNA expression.
This table summarizes RABGAP1L-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RABGAP1L-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RABGAP1L-DT shows lower tumor expression in KIRP, KIRC, KICH and THCA and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher RABGAP1L-DT RNA expression in tumor versus normal tissue (log2 FC = +0.528, t-test p < 0.001).
This table shows molecular features associated with RABGAP1L-DT in patient tissues and cancer cell lines. In patient samples, RABGAP1L-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
